Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise druggable by small molecules and biologics.
Arrowhead has built an experienced team of leaders that foster a culture of innovation and have a proven ability to advance development programs from idea stage into commercial pharmaceutical products.
Nanotech Business and Law Expert to Join Arrowhead - News Item
Caltech and Arrowhead Research Agree to Form Nanokinetics - News Item
Arrowhead Invests In Insert Therapeutics For Nanotech Drug Delivery Systems - News Item
President Named For Arrowhead Nanotech Subsidiary, Aonexx Technologies - News Item
Arrowhead Research Corporation to Form New Nanotech Subsidiary - News Item
Korea-Based Wisepower Acquires Arrowhead's Subsidiary
Arrowhead Opens New Nanomedicine Company to Commercicalize Anti-Obesity Technology
Unidym Signs Contract with Samsung to Manufacture Carbon Nanotubes
Calando Pharmaceuticals and Nanotope Receive Funds under U.S. Government’s QTDP Program
Nanotope Teams Up with Smith + Nephew to Develop Cartilage Regeneration Product
Nanotechnology Firm, Arrowhead Updates Shareholders on Business Operations
Arrowhead to Discuss its Nanomedicine Portfolio at Bio Investor Forum
Arrowhead Research CEO to Discuss Company’s Focus on Nanomedicine
Pioneer in Nanomedicine Joins Arrowhead’s Board of Directors
Arrowhead Research Enters Option Agreement for Obesity-Treating Technology
Leonardo Secures Grant to Commercialize Nanoparticle Drug Delivery System
Phase 1 CALAA-001 Clinical Trial Shows Systemic siRNA Delivery via Targeted Nanoparticles
Arrowhead Appoints Dr. Andrew von Eschenbach to its Scientific Advisory Board
Arrowhead Research Corporation Appoints New Member to its Scientific Advisory Board
Leader in Carbon Nanotube Technology Announces Partnership with Continental Carbon Company
Arrowhead Increases Ownership in Market Leader in Carbon Nanotube Technology
Arrowhead Research Corporation to Consolidate its Carbon Nanotube Production Capabilities
Prof. Hongxia Wang
We speak with Professor Hongxia Wang from QUT about a new project that hopes to utilize graphene and other low-cost carbon materials to produce commercially viable, ultra low-cost, flexible perovskite solar cells.
Moti Segev & Vlad Shalaev
In this interview, AzoNano speaks to Professor Moti Segev and Professor Vladimir Shalaev, who made surprising discoveries about photonic time crystals that challenge existing research and theories.
Siyu Chen, Ph.D.
In this interview, we discuss a new approach to surface-enhanced Raman spectroscopy that utilizes nano-pockets to capture target molecules, ensuring a highly sensitive way to detect chemical processes.
This product profile from Merck outlines information about ultrastable fluorescent silica nanobeads.
The ClearView scintillator camera that elevates your everyday transmission electron microscopy (TEM).
Achieve high-throughput co-localized imaging and in-situ nanoindentation with Bruker’s Hysitron PI 89 Auto SEM.